Top Cancer Researcher Fails To Disclose Corporate Financial Ties In Major Research Journals

The chief executive of Memorial Sloan Kettering, Dr. Craig B. Thompson, settled lawsuits several years ago that were filed by the University of Pennsylvania and an affiliated research center. They contended that he hid research conducted while he was at Penn to start a new company, Agios Pharmaceuticals, and did not share the earnings. Dr. Thompson disputed the allegations. He now sits on the board of Merck, which manufactures Keytruda, a blockbuster cancer therapy.

Ms. Hickey said the cancer center cannot fulfill its charitable mission without working with industry. “We encourage collaboration and are proud that our work has led to the approval of novel, lifesaving cancer treatments for patients around the world,” she said.

After the scandals a decade ago over lack of disclosure, the federal government began requiring drug and device manufacturers to publicly disclose payments to doctors in 2013.

From August 2013 through 2017, Dr. Baselga received nearly $3.5 million from nine companies, according to the federal Open Payments database, which compiles disclosures filed by drug and device companies.

Dr. Baselga has disclosed in other forums investments and advisory roles in biotech start-ups, but he declined to provide a tally of financial interests in those firms. Companies that have not received approval from the Food and Drug Administration for their products — projects still in the testing phases — do not have to report payments they make to doctors.

Serving on boards can be lucrative. In 2017, he received $260,000 in cash and stock awards to sit on Varian’s board of directors, according to the company’s corporate filings.

ProPublica and The Times analyzed Dr. Baselga’s publications in medical journals since 2013, the year he joined Memorial Sloan Kettering. He failed to disclose any industry relationships in more than 100, or about 60 percent of the time, a figure that has increased with each passing year. Last year, he did not list any potential conflicts in 87 percent of the articles that he wrote or co-wrote.

Source : https://www.nytimes.com/2018/09/08/health/jose-baselga-cancer-memorial-sloan-kettering.html

374
Top Cancer Researcher Fails To Disclose Corporate Financial Ties In Major Research Journals

Source:The Seattle Times

Top Cancer Researcher Fails To Disclose Corporate Financial Ties In Major Research Journals

Top Cancer Researcher Fails To Disclose Corporate Financial Ties In Major Research Journals

Source:Truthdig

Top Cancer Researcher Fails To Disclose Corporate Financial Ties In Major Research Journals

Top Cancer Researcher Fails To Disclose Corporate Financial Ties In Major Research Journals

Source:The Telegraph

Top Cancer Researcher Fails To Disclose Corporate Financial Ties In Major Research Journals

Top Cancer Researcher Fails To Disclose Corporate Financial Ties In Major Research Journals

Source:ProPublica

Top Cancer Researcher Fails To Disclose Corporate Financial Ties In Major Research Journals